We transfected MAPKi-resistant MRA5 and MAPKi-sensitive MRA6 metastatic melanoma cells with control or DUSP1 or DUSP8 siRNA and then treated the cells with 10 μM BRAFi or MEKi alone or in combination. This evidence concerns the gene DUSP8 and melanoma.